Cargando…

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL

Detalles Bibliográficos
Autores principales:	Agrawal, Rohitashva, Munker, Reinhold, Krem, Maxwell M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176010/ https://www.ncbi.nlm.nih.gov/pubmed/35847708 http://dx.doi.org/10.1002/jha2.78

Ejemplares similares

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
por: Haage, Tobias R., et al.
Publicado: (2022)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
por: Sethi, Supreet, et al.
Publicado: (2020)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
por: Atay, Didem, et al.
Publicado: (2012)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Successful treatment of hairy cell leukemia variant with obinutuzumab
por: Al-Sarayfi, Diana, et al.
Publicado: (2021)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
por: Elias, Shlomo, et al.
Publicado: (2018)

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
por: Wróbel, Tomasz, et al.
Publicado: (2023)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Early Profound Secondary Autoimmune Thrombocytopenia Induced by Clopidogrel in a Patient with a Coronary Artery Stent
por: Karakuş, Volkan, et al.
Publicado: (2012)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
por: Schwaner, Ingo, et al.
Publicado: (2023)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013
por: Eyckmans, Tom, et al.
Publicado: (2014)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
por: Blase, Jennifer R., et al.
Publicado: (2022)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

OA19 A case of severe refractory lupus enteritis and nephritis that remitted with Obinutuzumab
por: Chakravorty, Mithun, et al.
Publicado: (2022)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
por: Greil, Richard, et al.
Publicado: (2021)

Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
por: Kvacskay, Peter, et al.
Publicado: (2022)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
por: Nambiar, Vivek, et al.
Publicado: (2016)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgi66gc59k8lq4cn6c9c9vhb31